Iron overload in myelodysplastic syndromes

April 2010
American Journal of Health-System Pharmacy;4/1/2010 Supplement, Vol. 67, pS16
Academic Journal
A quiz concerning the epidemiology of iron overload and myelodysplastic syndromes (MDS) is presented.


Related Articles

  • Increased parameters of oxidative stress and its relation to transfusion iron overload in patients with myelodysplastic syndromes. de Souza, Geane Felix; Barbosa, Maritza Cavalcante; de Jesus Santos, Talyta Ellen; de Jesus Ponte Carvalho, Teresa Maria; de Freitas, Rivelilson Mendes; Alves Martins, Manoel Ricardo; Gonçalves, Romélia Pinheiro; Pinheiro, Ronald Feitosa; Magalhães, Silvia Maria Meira // Journal of Clinical Pathology;Nov2013, Vol. 66 Issue 11, p996 

    The article reports on research which was conducted to investigate increased parameters of oxidative stress and its relation to transfusion iron overload in patients with myelodysplastic syndromes. Researchers evaluated 20 patients with iron overload and 56 without. They found that a...

  • Iron overload in myelodysplastic syndromes. Harvey, R. Donald; Fausel, Christopher A. // American Journal of Health-System Pharmacy;4/1/2010 Supplement, Vol. 67, pS2 

    The article focuses on iron overload, a clinical complication resulted from myelodysplastic syndromes (MDS). It discusses the importance of management strategies in patients with MDS to address the consequences of overload, and the use of iron chelation therapy (ICT) as a treatment for MDS. It...

  • Understanding Iron Overload. Ault, Patricia; Jones, Karen // Clinical Journal of Oncology Nursing;Oct2009, Vol. 13 Issue 5, p511 

    Patients receiving recurring blood transfusions as supportive therapy to treat chronic anemias, such as myelodysplastic syndromes, thalassemia, and sickle-cell disease, are at risk of iron accumulation. The clinical consequences of iron overload are progressive liver damage, cardiac disease, and...

  • Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload. Nolte, F.; Höchsmann, B.; Giagounidis, A.; Lübbert, M.; Platzbecker, U.; Haase, D.; Lück, A.; Gattermann, N.; Taupitz, M.; Baier, M.; Leismann, O.; Junkes, A.; Schumann, C.; Hofmann, W.; Schrezenmeier, H. // Annals of Hematology;Feb2013, Vol. 92 Issue 2, p191 

    The majority of patients with myelodysplastic syndrome (MDS) present with anemia and will become dependent on regular transfusions of packed red blood cells (PRBC) with the risk of iron overload (IOL). Liver iron content best reflects the total body iron content, and measurement of liver iron...

  • Iron overload should be monitored in transfused patients with MDS. Green, Ralph // Hem/Onc Today;3/10/2008, Vol. 9 Issue 4, p50 

    This article focuses on a recommendation from the National Comprehensive Cancer Network, which stressed the need for regular monitoring of iron load in patients with myelodysplastic syndromes who are receiving red blood cell (RBC) transfusions. Findings from several studies suggested that iron...

  • Managing Iron Overload in Patients with Myelodysplastic Syndromes with Oral Deferasirox Therapy. JABBOUR, ELIAS; GARCIA-MANERO, GUILLERMO; TAHER, ALI; KANTARJIAN, HAGOP M. // Oncologist;May2009, Vol. 14 Issue 5, p489 

    Patients with myelodysplastic syndromes (MDS) often require chronic RBC transfusions, which can lead to iron overload. Without adequate management, this may cause progressive damage to hepatic, endocrine, and cardiac organs, significantly affecting overall survival. Recent retrospective analyses...

  • Management of Transfusion-Related Iron Overload in Patients With Myelodysplastic Syndromes. Shah, Jayshree; Kurtin, Sandra E.; Arnold, Louise; Lindroos-Kolqvist, Petra; Tinsley, Sara // Clinical Journal of Oncology Nursing;Jun2012 Supplement, Vol. 16, p37 

    Anemia is a common symptom for patients with myelodysplastic syndromes (MDS), a spectrum of hematopoietic malignancies characterized by ineffective hematopoiesis; 90% of these patients will become transfusion dependent (TD). Because of the closed nature of iron metabolism, the repeated input of...

  • Optimizing Therapy for Iron Overload in the Myelodysplastic Syndromes. Leitch, Heather A. // Drugs;2011, Vol. 71 Issue 2, p155 

    The myelodysplastic syndromes (MDS) are characterized by cytopenias and risk of progression to acute myeloid leukaemia (AML). Most MDS patients eventually require transfusion of red blood cells for anaemia, placing them at risk of transfusional iron overload. In ß-thalassaemia major,...

  • The Role of the Iron Transporter ABCB7 in Refractory Anemia with Ring Sideroblasts. Boultwood, Jacqueline; Pellagatti, Andrea; Nikpour, Maryam; Pushkaran, Beena; Fidler, Carrie; Cattan, Helen; Littlewood, Tim J.; Malcovati, Luca; Porta, Matteo G. Della; Jädersten, Martin; Killick, Sally; Giagounidis, Aristoteles; Bowen, David; Hellström-Lindberg, Eva; Cazzola, Mario; Wainscoat, James S. // PLoS ONE;2008, Vol. 3 Issue 4, p1 

    Refractory Anemia with Ring Sideroblasts (RARS) is an acquired myelodysplastic syndrome (MDS) characterized by an excess iron accumulation in the mitochondria of erythroblasts. The pathogenesis of RARS and the cause of this unusual pattern of iron deposition remain unknown. We considered that...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics